EBC

ENG

lidERA, ALTTO

SABCS 2025

A milestone for ET in HR+ HER2- and important follow-up…

V. Diéras, A. Gennari, V. Guarneri, D. Lüftner, A. Schneeweiss, E. Senkus-Konefka

ENG

PREFER, OlympiaN

SABCS 2025

Important new data for young breast cancer patients

V. Diéras, N. Harbeck, W. Janni, B. Pistilli, H. Rugo, M. Untch

ABC

ENG

EMBER-3, evERA, ELEVATE

SABCS 2025

Where is the future of SERDs in MBC?

V. Diéras, N. Harbeck, W. Janni, B. Pistilli, H. Rugo, M. Untch

ENG

AMBRE, ASCENT-07, Her2climb-05

SABCS 2025

Firstline treatment of MBC: Which strategy is best?

V. Diéras, A. Gennari, V. Guarneri, D. Lüftner, V. Müller, E. Senkus-Konefka

EBC 100 seconds

ENG

SABCS 2025

Patients contribution is essential

Volkmar Müller, MD

ENG

Axsana

SABCS 2025

Axilla dissection - less is more

Wolfgang Janni, MD

HR+

ENG

PALLAS

SABCS 2025

PALLAS trial and ctDNA

Peter A. Fasching, MD

ENG

LORETTA

SABCS2025

Surgery remains soc in low risk EBC

Alessandra Gennari, MD, PhD

ENG

lidERA

SABCS 2025

Giredestrant will replace current adjuvant therapy

Diana Lüftner, MD

ENG

lidERA

SABCS 2025

Revolution in adjuvant endocrine therapy?

Michael Untch, MD

ENG

NSABP B-20

SABCS 2025

AI based prognostic test

Nadia Harbeck, MD, PhD

ENG

ALTTO

SABCS 2025

Therapy optimization: Endocrine approaches in…

Evandro de Azambuja, MD, PhD

ENG

lidERA

SABCS 2025

SERDs in early breast cancer - the new era has begun?

Elzbieta Senkus-Konefka, MD

ENG

ALTTO

SABCS 2025

ALTTO trial outcome according to endocrine therapy

Valentina Guarneri, MD, PhD

ENG

lidERA

SABCS 2025

SERDs now in adjuvant therapy

Peter A. Fasching, MD

HER2+

ENG

DESTINY-Breast05, DESTINY-Breast11, Destiny-Breast09

SABCS 2025

Significant innovations in early and metastatic HER2+…

Michael Untch, MD

ENG

PHERGain

SABCS 2025

ctDNA analysis could optimize the approach in HER2+

Javier Cortés, MD, PhD

ENG

DESTINY-Breast11

SABCS 2025

Quality of live data DB11

Nadia Harbeck, MD, PhD

ENG

APHINITY

SABCS 2025

sTILs with deep learning AI

Diana Lüftner, MD

ENG

DESTINY-Breast11

SABCS 2025

Safety data DB11

Nadia Harbeck, MD, PhD

ENG

ALTTO

SABCS 2025

Optimized endocrine therapy for premenopausal patients

Diana Lüftner, MD

TNBC

ENG

RJBC 1501, CITRINE

SABCS 2025

Carboplatin in adjuvant setting of TNBC

Valentina Guarneri, MD, PhD

ENG

RJBC 1501, CITRINE

SABCS 2025

Platinum adjuvant in TNBC

Michael Untch, MD

ENG

NSABP-B59/GBG-96-GeparDouze

SABCS 2025

In addition to pCR, ctDNA is prognostically relevant…

Andreas Schneeweiss, MD

ENG

OlympiaN

SABCS 2025

Olaparib neoadjuvant with high PCR rates

Peter A. Fasching, MD

Multilanguage

POL

lidERA

SABCS 2025

SERDy we wczesnym raku piersi -początek nowej epoki?

Elzbieta Senkus-Konefka, MD

ITA

RJBC 1501, CITRINE

SABCS 2025

Carboplatino nel contesto adiuvante del TNBC

Valentina Guarneri, MD, PhD

ITA

ALTTO

SABCS 2025

Risultati dello studio ALTTO in base alla terapia…

Valentina Guarneri, MD, PhD

ITA

LORETTA

SABCS 2025

La chirurgia rimane lo standard di cura nei casi di…

Alessandra Gennari, MD, PhD

POR

ALTTO

SABCS 2025

Otimização da terapia: abordagens endócrinas em…

Evandro de Azambuja, MD, PhD

ESP

PHERGain

SABCS 2025

El análisis del ADN libre circulante podría optimizar…

Javier Cortés, MD, PhD

HR+

ENG

PATINA

SABCS 2025

Palbociclib likely delays CNS progression

Andreas Schneeweiss, MD

ENG

ELEVATE

SABCS 2025

Phase 2 combination of elacestrant with everolimus or…

Hope Rugo, MD

ENG

evERA BC

SABCS 2025

Biomarker and clinical subgroup analysis of evERA…

Hope Rugo, MD

ENG

ASCENT-07

SABCS 2025

ASCENT-07 a negative trial

Diana Lüftner, MD

ENG

VIKTORIA-1

SABCS 2025

Updated results of VIKTORIA-1

Barbara Pistilli, MD

ENG

Detect-V

SABCS 2025

Triple-positive MBC: less chemotherapy, more endocrine…

Wolfgang Janni, MD

ENG

DETECT V

SABCS 2025

Chemotherapy-free treatment: a promising therapeutic…

Andreas Schneeweiss, MD

ENG

ASCENT-07

SABCS 2025

No improvement over standard therapy

Evandro de Azambuja, MD, PhD

ENG

ELEVATE

SABCS 2025

Elacestrant as oral endocrine backbone

Carmen Criscitiello, MD, PhD

ENG

ASCENT-07

SABCS 2025

Traditional chemotherapy should not be forgotten as…

Elzbieta Senkus-Konefka, MD

ENG

Ascent-07

SABCS 2025

The significance of SG is more clearly defined

Wolfgang Janni, MD

ENG

P-RAD

SABCS 2025

Make a hot tumor out of a cold tumor

Diana Lüftner, MD

ENG

ELEVATE

SABCS 2025

Elacestrant is a good combination partner for HR+ HER2+…

Andreas Schneeweiss, MD

HER2+

ENG

EMBER-3

SABCS 2025

New evidence for oral SERDs

Alessandra Gennari, MD, PhD

DESTINY-Breast05

SABCS 2025

Monitoring of ILD

Diana Lüftner, MD

ENG

AMBRE

SABCS 2025

CDK4/6 inhibitor + endocrine therapy remains the…

Andreas Schneeweiss, MD

ENG

Her2climb-05

SABCS 2025

Maintenance therapy HER2+ Tucatinib as a new option

Volkmar Müller, MD

ENG

EMBER-3

SABCS 2025

ctDNA Dynamics as a biomarker of response

Carmen Criscitiello, MD, PhD

ENG

Her2climb-05, Ambre

SABCS 2025

Tucatinib a new SERD in the adjuvant setting

Véronique Diéras, MD

ENG

DESTINY-Breast05, DESTINY-Breast11, Destiny-Breast09

SABCS 2025

Significant innovations in early and metastatic HER2+…

Michael Untch, MD

Multilanguage

ITA

ELEVATE

SABCS 2025

Elacestrant come partner endocrino orale

Carmen Criscitiello, MD, PhD

ITA

EMBER-3

SABCS 2025

Nuove prove a favore dei SERD orali

Alessandra Gennari, MD, PhD

FRA

VIKTORIA-1

SABCS 2025

Résultats actualisés de VIKTORIA-1

Barbara Pistilli, MD

POL

ASCENT-07

SABCS 2025

Jeszcze nie czas na rezygnację z tradycyjnej…

Elzbieta Senkus-Konefka, MD

EMBER-3

SABCS 2025

La dinamica del ctDNA come biomarcatore di risposta

Carmen Criscitiello, MD, PhD

ITA

VIKTORIA-1

SABCS 2025

Risultati aggiornati di VIKTORIA-1

Barbara Pistilli, MD

FRA

Her2climb-05, Ambre

SABCS 2025

Tucatinib, un nouveau SERD dans le cadre d'un…

Véronique Diéras, MD

POR

ASCENT-07

SABCS 2025

Sem melhorias em relação à terapia padrão

Evandro de Azambuja, MD, PhD

Poster Insights

ENG

MonarchE

SABCS 2025

MonarchE: subgroup analysis of adjuvant abemaciclib +…

Javier Cortés, MD, PhD